|
June 2000
Second Wind
Lomita, California
Dear Friends:
New developments in our understanding of the basic underlying
inflammatory processes involved in the development of COPD, will
soon lead to new therapeutic approaches. Recent science has shown
that the inflammatory mechanisms involved in COPD are quite different
from asthma. This is why the corticosteroid derivative, given
orally as prednisone, and by the inhaled route with numerous preparations,
are not nearly as effective in COPD as they are in asthma. A new
family of drugs, called the phosphodiesterase-4 inhibitors are
specifically designed to deal with COPD mechanisms. Already one
drug, which will be marketed as "Ariflo", probably in about two
to three years, appears extremely promising.
A new inhaled bronchodilator, related to ipratropium, (Atrovent)
is also in the wing. It is a 24-hour potent inhaled agent that
promises to replace existing bronchodilators. This drug will be
marketed as "Spiriva", by Boehringer Ingelheim. What a great name.
Spiriva literally means, 'the breath of life'.
Couple these new developments with the emerging National Lung
Health Education Program, (NLHEP), which is now calling for all
primary care physicians to do simple spirometry in their offices
for early identification of COPD and related disorders, and we
have a potential revolution going on. You can't treat a disease
until you diagnose it, of course. By involving all primary care
physicians in the use of simple, easy to use spirometers for office
testing, we will probably find the 15 to 16 million unidentified
patients with early stage COPD. Now, if we can curtail smoking
in these patients, and deal with the underlying inflammatory and
bronchospastic processes with these new drugs, we can probably
prevent the progress of disease. Improving symptoms and the quality
of life is a top priority, but also preventing and forestalling
premature symptoms and death is the major challenge. Thus, the
future of COPD looks very bright, but it would be brightest of
all if no one ever started smoking.
I will be in touch next month
Your friend,

Thomas Petty, MD
|